Diabetes: Several compounds in G. lucidum (including polysaccharides, proteoglycans, proteins and triterpenoids) may have hypoglycemic effects. In vitro evidence suggests that protein tyrosine phosphatase 1B is a promising therapeutic target in diabetes, and a G. lucidum proteoglycan can inhibit this enzyme. Secondly, G. lucidum demonstrates inhibition of aldose reductase and α-glucosidase, which can suppress postprandial hyperglycemia. A proteoglycan enhanced insulin secretion and decreasing hepatic glucose output (along with increased adipose and skeletal muscle glucose disposal) and normalized serum lipids in a murine model of diabetes. A polysaccharide also demonstrated hypoglycemic effects in type 2 diabetic mice.